Astoria Portfolio Advisors’s Moderna MRNA Stock Holding History

Astoria Portfolio Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,323	Closed	-$257K	–	210
2022 Q4	$257K	Buy	+1,323	New	+$216K	0.12%	165

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Astoria Portfolio Advisors's MRNA Position: Q1 2023 in Review

Astoria Portfolio Advisors sold out of Moderna (MRNA) in Q1 2023, closing a stake of 1,323 shares — an estimated $257K sold.

Astoria Portfolio Advisors first reported a position in MRNA in Q4 2022 and held it in 1 quarter. The position peaked at $257K in Q4 2022. 1,015 funds tracked by Wall St. Rank hold MRNA as of Q1 2023.

Astoria Portfolio Advisors reported no remaining Moderna position as of Q1 2023 after selling out during the quarter.
Astoria Portfolio Advisors sold 1,323 Moderna shares in Q1 2023, an estimated $257K.
Astoria Portfolio Advisors first reported a position in Moderna in Q4 2022 and held it in 1 quarter.
Astoria Portfolio Advisors's Moderna position peaked at $257K in Q4 2022.
1,015 funds tracked by Wall St. Rank held Moderna as of Q1 2023.

Based on Astoria Portfolio Advisors's 13F filing for Q1 2023, filed 5 Apr 2023.